Name: Latest research reports of GlaxoSmithKline Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: GlaxoSmithKline Pharmaceuticals Ltd.
Rating: 3
Author: Motilal Oswal

GlaxoSmithKline Pharmaceuticals Ltd.

NSE: GLAXO | BSE: 500660 | ISIN: INE159A01016 | Industry: Pharmaceuticals
| Mid-range Performer

2734.9000 -93.90 (-3.32%)

NSE Aug 06, 2025 15:53 PM

42.37% Gain from 52W Low

Volume: 90,193

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024, 12:00AM

2734.90

-3.32%

Superior execution and lower RM costs drive earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Glaxo Pharma (GLXO) delivered better-than-expected 1QFY25 performance. The robust growth in key brands, young potential brands.

GlaxoSmithKline Pharmaceuticals Ltd. has lost -13.18% in the last 1 Week

Trendlyne Marketwatch | 06 Aug 2025, 03:56PM

Five stocks to buy from analysts this week - August 6, 2025

The Baseline | 06 Aug 2025, 10:55AM

IPO calendar fills up: 12 new issues, and 12 listings this week

| 04 Aug 2025